STARPAX BIOPHARMA
LIVE

Serial Number

79354996

Owner

Starpax Biopharma Inc.

Attorney

Michelle P. Ciotola

Filing Date

Jun 20, 2022

Add to watchlist:

No watchlists yet
View on USPTO

STARPAX BIOPHARMA Trademark

Serial Number: 79354996 • Registration: 7333932

STARPAX BIOPHARMA is a trademark filed by Starpax Biopharma Inc. on June 20, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Starpax Biopharma Inc. (5 trademarks)

6615 Rue Abrams

Entity Type: 03

Médical Starpax Inc./ Starpax Medical Inc. (2 trademarks)

1100 Boul René-Lévesque O

Entity Type: 03

Trademark Details

Filing Date

June 20, 2022

Registration Date

March 26, 2024

Published for Opposition

January 9, 2024

Goods & Services

Anti-cancer preparations; bacteria capable to transport therapeutic agents and imagery markers into cancer tumors and organs for the treatment of cancer and other diseases requiring targeted delivery; bacteria capable to transport therapeutic agents and imagery markers into organs for the treatment of diseases or disorders located in low oxygen areas of the human body and the animal body; pharmaceutical preparations and compositions for the treatment and prevention of cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; pharmaceutical preparations and substances for the treatment of cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; therapeutic agents and imagery markers for delivery of cancer treatment

Health care services for treating cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; medical analysis services for cancer diagnosis and prognosis; medical diagnostic services

Pharmaceutical research and development; medical and scientific research, namely, conducting clinical trials for others for pharmaceutical preparations used for the treatment of cancer, immunological, inflammatory and infectious diseases, and pain

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 9, 2024 FINV
NEW REPRESENTATIVE AT IB RECEIVED
Oct 18, 2024 NREP
GENERIC MADRID TRANSACTION SENT TO IB
Oct 17, 2024 XXSS
GENERIC MADRID TRANSACTION CREATED
Oct 16, 2024 XXCR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 13, 2024 ADCH
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 27, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 26, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 26, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 9, 2024 PUBO
NOTIFICATION PROCESSED BY IB
Jan 8, 2024 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 20, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 20, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 20, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 6, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 6, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 5, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 5, 2023 TROA
REFUSAL PROCESSED BY IB
Jun 26, 2023 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 7, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jun 6, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 14, 2023 RFCR
NON-FINAL ACTION WRITTEN
Apr 13, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 30, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 18, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 14, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 10, 2022 REPR